


Pharmaceuticals & Biotechnology | Small Cap
Nectar Lifescience Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strengths in solvency and profitability, driven by a solid equity base and returns on capital employed, alongside prudent capital expenditure management. However, it faces challenges in liquidity, growth, and efficiency, which are areas needing attention. The absence of revenue growth and low coverage ratios are significant concerns. While the company maintains a strong equity position, improvements in operational efficiency and revenue generation are crucial for sustained financial health and future prospects.
Nectar Lifescience Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strengths in solvency and profitability, driven by a solid equity base and returns on capital employed, alongside prudent capital expenditure management. However, it faces challenges in liquidity, growth, and efficiency, which are areas needing attention. The absence of revenue growth and low coverage ratios are significant concerns. While the company maintains a strong equity position, improvements in operational efficiency and revenue generation are crucial for sustained financial health and future prospects.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-1.69
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
-2.67
P/B RATIO
0.32
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
0.18
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-13.79
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹13.56 as on Jun 15, 2026.
The company's growth ratios are generally poor. The absence of revenue and net income growth, combined with negative growth in operating profit, earnings per share, and assets, indicates significant challenges in expanding its business. This suggests a need for strategic initiatives to stimulate growth and improve financial performance. Current trends pose a risk to future sustainability.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 8.05 | -8.71 | 10.66 | -1.07 | -99.88 |
| Operating Profit Growth Rate | 45.87 | -66.67 | 186.79 | -119.74 | 96.67 |
| Earnings Per Share (EPS) Growth | -134.25 | -196.43 | -120.37 | -2404.55 | 197.44 |
| Asset Growth Rate | 0.13 | -8.45 | 0.09 | -6.57 | -69.61 |
| Net Income Growth Rate | -134.25 | -196 | -120.83 | -2380 | 157.02 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 2 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 3 | SMS Lifesciences India Ltd | 6.59 | 21.63 | Undervalued | 45.00 | 58.80 | 19.00 |
| 4 | Infinium Pharmachem Ltd | 6.42 | 26.92 | Neutral | 22.00 | 6.43 | 14.00 |
| 5 | Medicamen Biotech Ltd | 5.73 | 33.43 | Neutral | 20.00 | 6.94 | 10.00 |
| 6 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 58.43 | Neutral | 7.00 | 1.40 | 4.00 |
| 7 | Albert David Ltd | 5.63 | -279.90 | Neutral | 5.00 | -2.62 | -1.00 |
| 8 | BPL Ltd | 5.46 | -30.53 | Neutral | -4.82 | -1.69 | -8.55 |
| 9 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 10 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 11 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Quarterly Report⬤23rd Jan 26
Quarterly Financial Results Q3 FY 2025-26
BEARISH SENTIMENT